Patents by Inventor Dietrich Stephan

Dietrich Stephan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210324012
    Abstract: The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which can include administration of oligonucleotide analogues that can bind pathogenic nucleotide repeats in DNA or RNA.
    Type: Application
    Filed: April 15, 2021
    Publication date: October 21, 2021
    Inventors: Danith H. LY, Shivaji A. THADKE, Ramesh U. BATWAL, Valentina DI CARO, Dietrich A. STEPHAN, Letha J. SOOTER, Samuel I. BACKENROTH
  • Publication number: 20210309997
    Abstract: The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which can include administration of oligonucleotide analogues that can bind pathogenic nucleotide repeats in DNA or RNA.
    Type: Application
    Filed: March 30, 2021
    Publication date: October 7, 2021
    Inventors: Danith H. LY, Shivaji A. THADKE, Ramesh U. BATWAL, Valentina DI CARO, Dietrich A. STEPHAN, Letha J. SOOTER, Samuel I. BACKENROTH
  • Publication number: 20210309700
    Abstract: The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which can include administration of oligonucleotide analogues that can bind pathogenic nucleotide repeats in DNA or RNA.
    Type: Application
    Filed: April 15, 2021
    Publication date: October 7, 2021
    Inventors: Danith H. LY, Shivaji A. THADKE, Ramesh U. BATWAL, Valentina DI CARO, Dietrich A. STEPHAN, Letha J. SOOTER, Samuel I. BACKENROTH
  • Publication number: 20190271044
    Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
    Type: Application
    Filed: October 8, 2018
    Publication date: September 5, 2019
    Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
  • Publication number: 20160362749
    Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
    Type: Application
    Filed: June 15, 2016
    Publication date: December 15, 2016
    Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
  • Publication number: 20160122830
    Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
    Type: Application
    Filed: October 28, 2015
    Publication date: May 5, 2016
    Inventors: Dietrich STEPHAN, Vern NORVIEL, Janet WARRINGTON, Doug DOLGINOW
  • Publication number: 20160115554
    Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
    Type: Application
    Filed: October 29, 2015
    Publication date: April 28, 2016
    Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
  • Publication number: 20160115553
    Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
    Type: Application
    Filed: October 28, 2015
    Publication date: April 28, 2016
    Inventors: Dietrich STEPHAN, Vern NORVIEL, Janet WARRINGTON, Doug DOLGINOW
  • Patent number: 9092391
    Abstract: The present invention provides methods of determining a Genetic Composite Index score by assessing the association between an individual's genotype and at least one disease or condition. The assessment comprises comparing an individual's genomic profile with a database of medically relevant genetic variations that have been established to associate with at least one disease or condition.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: July 28, 2015
    Assignee: Navigenics, Inc.
    Inventors: Dietrich A. Stephan, Melissa Floren Filippone, Jennifer Wessel, Michele Cargill, Eran Halperin
  • Publication number: 20140141980
    Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 22, 2014
    Applicant: Aueon, Inc.
    Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
  • Publication number: 20140141426
    Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 22, 2014
    Applicant: Aueon, Inc.
    Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
  • Publication number: 20140080733
    Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 20, 2014
    Applicant: Aueon, Inc.
    Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
  • Patent number: 8583380
    Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: November 12, 2013
    Assignee: Aueon, Inc.
    Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
  • Publication number: 20130109589
    Abstract: Methods for determining the genetic predisposition of a human subject to developing ALS are provided herein. These methods include methods for determining the genetic predisposition to any form of ALS, as well as specific methods for determining the genetic predisposition to early onset, late onset, bulbar onset and limb onset ALS. The method can detect amyotrophic lateral sclerosis in a human subject or a specific form of ALS in the subject (early onset, late onset, bulbar onset or limb onset). The method can also detect the risk of developing amyotrophic lateral sclerosis (ALS) in a human subject. The methods utilize the detection of one or more haplotype bocks comprising tag single nucleotide polymorphisms (SNPs). In several embodiments, the methods including detecting the presence of one or more tag SNPs.
    Type: Application
    Filed: December 17, 2012
    Publication date: May 2, 2013
    Applicant: Translational Genomics Research Institute
    Inventors: Dietrich Stephan, Matthew Huentelman, Travis Dunckley, Stephan Gately
  • Patent number: 8426130
    Abstract: The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: April 23, 2013
    Assignee: Translational Genomics Research Institute
    Inventors: Dietrich A. Stephan, Eric M. Reiman, Jennifer Webster, Andreas Papassotiropoulos, Pamela Heward
  • Publication number: 20130013217
    Abstract: The present disclosure provides methods and systems for assessing an individual's genotype correlations to a phenotype by analyzing the individual's genomic profile and using ancestral data to determine the correlations between genotypes and phenotypes.
    Type: Application
    Filed: September 12, 2012
    Publication date: January 10, 2013
    Applicant: NAVIGENICS, INC.
    Inventors: Dietrich A. STEPHAN, Jennifer Wessel, Michele Cargill, Eran Halperin
  • Publication number: 20110230360
    Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
    Type: Application
    Filed: September 4, 2009
    Publication date: September 22, 2011
    Applicant: Aueon ,Inc. a corporation
    Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
  • Patent number: 7993836
    Abstract: The present invention relates to DNA sequences associated with human memory performance. It also provides methods for (i) screening for diseases and pathological conditions affecting human memory, (ii) identifying agents useful for treatment of diseases and pathological conditions affecting human memory, and (iii) agents and compositions useful for treatment of diseases and pathological conditions affecting human memory.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: August 9, 2011
    Assignees: Translational Genomics Research Institute, University of Zurich
    Inventors: Andreas Papassotiropoulos, Dietrich Stephan, Dominique J.-F. De Quervain
  • Publication number: 20100293130
    Abstract: The present invention provides methods of determining a Genetic Composite Index score by assessing the association between an individual's genotype and at least one disease or condition. The assessment comprises comparing an individual's genomic profile with a database of medically relevant genetic variations that have been established to associate with at least one disease or condition.
    Type: Application
    Filed: November 30, 2007
    Publication date: November 18, 2010
    Inventors: Dietrich A. Stephan, Melissa Floren Filippone, Jennifer Wessel, Michele Cargill, Eran Halperin
  • Publication number: 20100216130
    Abstract: Methods for determining the genetic predisposition of a human subject to developing ALS are provided herein. These methods include methods for determining the genetic predisposition to any form of ALS, as well as specific methods for determining the genetic predisposition to early onset, late onset, bulbar onset and limb onset ALS. The method can detect amyotrophic lateral sclerosis in a human subject or a specific form of ALS in the subject (early onset, late onset, bulbar onset or limb onset). The method can also detect the risk of developing amyotrophic lateral sclerosis (ALS) in a human subject. The methods utilize the detection of one or more haplotype bocks comprising tag single nucleotide polymorphisms (SNPs). In several embodiments, the methods including detecting the presence of one or more tag SNPs.
    Type: Application
    Filed: November 29, 2007
    Publication date: August 26, 2010
    Inventors: Dietrich Stephan, Matthew Huentelman, Travis Dunckley, Stephen Gately